---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-127045"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:34:04.757701+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tivic Health Q3 revenue $126K, down 27% YoY; net loss narrows to $1.4M

## Summary
- Revenue for nine months ended Sep 30, 2024: $600K, down 27% vs 2023 on 36% fewer units sold.
- Net loss in Q3 2024 was $1.4M vs $1.8M in Q3 2023; operating expenses cut $1.9M YTD.
- Cash at Sep 30: $2.2M; raised $775K net in Oct-Nov via stock sales.
- Completed Phase 1a optimization study for non-invasive VNS; partnered with Fletcher Spaght.
- Appointed Lisa Wolf as interim CFO effective Oct 1; supply chain redesigned for higher margins.

## SEC filing metadata
- accession: 0000950170-24-127045
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017024127045/0000950170-24-127045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017024127045/tivc-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-127045
- JSON: https://secwatch.observer/filing/0000950170-24-127045.json
- Plain text: https://secwatch.observer/filing/0000950170-24-127045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.